Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group.
The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks. The trial was modified due to toxicity after the first 16 patients. IL-12 was given 300 ng/kg subcutaneously twice weekly for 24 weeks. Of 48 eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed.
Lacy
Martha Q
MQ
Division of Hematology, Mayo Clinic, Rochester, MN 55905, United States. lacy.martha@mayo.edu
Jacobus
Susanna
S
Blood
Emily A
EA
Kay
Neil E
NE
Rajkumar
S Vincent
SV
Greipp
Philip R
PR
D000328:Adult; D000368:Aged; D018791:CD4 Lymphocyte Count; D005260:Female; D006801:Humans; D018664:Interleukin-12 / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D016019:Survival Analysis; D016176:T-Lymphocyte Subsets
D018664:Interleukin-12